Protective Efficacy of a Recombinant DNA Hepatitis B Vaccine in Neonates of HBe Antigen—Positive Mothers

JAMA: The Journal of the American Medical Association

Volumn 261, Issue 22, 1989, Pages 3278-3281

  Poovorawan, Yong ^a   Sanpavat, Suvimol ^a   Pongpunlert, Wiroje ^a   Chumdermpadetsuk, Saowani ^a   Sentrakul, Prasertsri ^a   Safary, Assad ^a  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; MATERNAL ANTIBODY;

CHRONIC HEPATITIS; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; NEWBORN; PRIORITY JOURNAL;

CARRIER STATE; EVALUATION STUDIES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMAN; IMMUNITY, MATERNALLY-ACQUIRED; INFANT, NEWBORN; PREGNANCY; THAILAND; VACCINES, SYNTHETIC; VIRAL HEPATITIS VACCINES;

EID: 0024366759     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1989.03420220092033     Document Type: Article

References (36)

1. Ghendon Y. Perinatal transmission of hepatitis B virus in high-incidence countries. J Virol Methods. 1987;17:69-79.
2. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y, Mayumi M. e Antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med. 1976;294:746-749.
3. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977;105:94-98.
4. Lee AKY, Ip HMH, Wong VCW. Mechanisms of maternal-fetal transmission of hepatitis B virus. J Infect Dis. 1978;138:668-671.
5. Woo D, Cummins M, Davies PA, Harvey DR, Hurley R, Waterson AP. Vertical transmission of hepatitis B surface antigen in carrier mothers in two West London hospitals. Arch Dis Child. 1979;54:670-675.
6. Beasley RP, Hwang LY, Lee GCY, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2:1099-1102.
7. Wong VCW, IP HMH, Reesink HW, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B immunoglobulin. Lancet. 1984;1:921-926.
8. Xu ZY, Liu CB, Francis DP, et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics. 1985;76:713-718.
9. Pongpipat D, Suvatte V, Assateerawatts A. Efficacy of hepatitis B immunoglobulin and hepatitis B vaccine in prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg. Asian Pac J Allergy Immunol. 1986;4:33-36.
10. Iwarson SA. Chronic hepatitis B. In: Gereby RJ, ed. Hepatitis B. Orlando, Fla: Academic Press Inc; 1985:119-153.
11. Tabor E. Hepatitis B virus and primary hepatocellular carcinoma. In: Gerety RJ, ed. Hepatitis B. Orlando, Fla: Academic Press Inc; 1985:247-267.
12. Goudeau A, Lo KJ, Coursaget P, et al. Prevention of hepatitis B virus infection in children born to HBsAg positive/HBeAg positive mothers: preliminary results of active and passive-active immunization. Dev Biol Stand. 1983;54:399-404.
13. Lo KJ, Tsai YT, Lee SD, et al. Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatits B surface antigen-positive carrier mothers. J Infect Dis. 1985;152:817-822.
14. Boxall EH, Tarlow MJ. Hepatitis B vaccine in the prevention of perinatally transmitted hepatitis B virus infections: initial report of a study in the west midlands of England. J Med Virol. 1986;18: 255-260.
15. Farmer K, Gunn T, Woodfield DG. A combination of hepatitis B vaccine and immunoglobin does not protect all infants born to hepatitis B e antigen positive mothers. N Z Med J. 1987;100:412-414.
16. Wiedermann G, Scheiermann N, Goubau P, et al. Multicentre dose range study of a yeast-derived hepatitis B vaccine. Vaccine. 1987;5:179-183.
17. André FE, Safary A. Clinical experience with a yeast-derived hepatitis B vaccine. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York, NY: Alan R Liss Inc; 1988:1025-1030.
18. Goilav C, Prinsen H, Safary A, André FE, Piot P. Immunization of homosexual men with a recombinant DNA vaccine against hepatitis B: immunity and protection. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York, NY: Alan R Liss Inc; 1988:1057-1058.
19. Van Damme P, Vranckx R, Safary A, André F, Meheus A. Immunogenicity and efficacy of recombinant DNA hepatitis B vaccine in institutionalized mentally retarded patients: preliminary results. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York, NY: Alan R Liss Inc; 1988:1065-1067.
20. Schellekens H, De Reus A, Peetermans JH, Van Eerd PACM. The protection of chimpanzees against hepatitis B viral infection using a recombinant yeast-derived hepatitis B surface antigen. Postgrad Med J. 1987;63(suppl 2):93-96.
21. Meheus A, Alisjahbana A, Vranckx R, et al. Immunogenicity of a recombinant DNA hepatitis B vaccine in neonates. Postgrad Med J. 1987;63(suppl 2):139-141.
22. Cadranel S, Zeghlache S, Fernandez S, Safary A, Andre F. Vaccination of newborns of HBsAg positive carrier mothers with a recombinant DNA hepatitis B vaccine. Postgrad Med J. 1987;63(suppl 2):159-160.
23. Beasley RP, Hwang LY, Stevens CE, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind placebo-controlled trial. Hepatology. 1983;3:135-141.
24. De Wilde M, Cabezon T, Harford N, Rutgers T, Simoen E, Van Wijnendaele F. Production in yeast of hepatitis B surface antigen by r-DNA technology. Dev Biol Stand. 1985;59:99-107.
25. Pêtre J, Van Wijnendaele F, De Neys B, et al. Development of a hepatitis B vaccine from transformed yeast cells. Postgrad Med J. 1987;63:73-81.
26. Hauser P, Voet P, Simeon E, et al. Immunological properties of recombinant HBsAg produced in yeast. Postgrad Med J. 1987;63(suppl 2):83-91.
27. Shafritz SA, Lieberman HM, Isselbacher KJ, Wands JR. Monoclonal radioimmunoassays for hepatitis B surface antigen: demonstration of hepatitis B virus DNA or related sequences in serum and viral epitopes in immune complexes. Proc Natl Acad Sci USA. 1982;79:5675-5679.
28. Moriarty AM, Hoyter BH, Shih JW, Gerin JL, Hamer DH. Expression of the hepatitis B virus surface antigen genes in cell culture by using a simian virus 40 vector. Proc Natl Acad Sci USA. 1981;78:2606-2610.
29. Rigby PWJ, Dieckman M, Rhodes C, Berg P. Labeling desoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I. J Mol Biol. 1977;113:237-251.
30. Stevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission in the United States. JAMA. 1985;253:1740-1745.
31. Chung WK, Yoo JY, Sun HS, et al. Prevention of perinatal transmission of hepatitis B virus: a comparison between the efficacy of passive and passive-active immunization in Korea. J Infect Dis. 1985;151:280-286.
32. Oon CJ, Tan KL, Goh KT, et al. Evaluation of a low dose of hepatitis B vaccine given within a childhood immunization programme in Singapore. J Infect. 1986;13:255-267.
33. Yeoh EK, Chang WK, Ip P, Chan KH, Chan E, Fung C. Efficacy and safety of recombinant hepatitis B vaccine in infants born to HBsAg-positive mothers. J Infect. 1986;13(suppl A):15-18.
34. Zanetti AR, Dentico P, Del Vecchio Blanco C, et al. Multicenter trial on the efficacy of HBIG and vaccine in preventing perinatal hepatitis B final report. J Med Virol. 1986;18:237-334.
35. Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA. 1987;257: 2612-2616.
36. Hsu HM, Chen DS, Chuang CH, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. JAMA. 1988:260:2231-2235.